Summary

The AMDS PERSEVERE trial recently announced significant data, which serves as a critical late-breaking news for thoracic surgery. Researchers successfully delivered this presentation at the Society of Thoracic Surgeons Annual Meeting in Los Angeles, California, highlighting crucial developments for the field. This specific announcement occurred on December 9, 2024, when Artivion officially received a Humanitarian Device Exemption for the AMDS Hybrid Prosthesis. The exemption allows these devices to be used in acute DeBakey Type I dissections, particularly in cases involving malperfusion. This groundbreaking grant represents a major milestone for patients recovering from complex chest and abdomen surgeries, proving these implants are safer and more effective than previous technologies. The combination of this trial data and the Artivion approval ensures that future surgical procedures can rely on these proven hybrid prosthesis solutions, even when complications arise.

Title

Homepage - Artivion

Description

Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with diseases of the aorta and to deliver breakthrough technologies of unsurpassed quality that have far-reachin

Keywords

amds, adhesive, syringe, stent, system, there, patient, versions, graft, data, heart, valve, hybrid, trial, prosthesis, acute, type

NS Lookup

A 35.199.179.76

Dates

Created 2026-04-12

Updated 2026-04-22

Summarized 2026-04-24